More people may soon be able to get the obesity treatment they need. Beginning July 1, eligible Medicare Part D beneficiaries may be able to get certain obesity medicines for weight management through Medicare GLP-1 Bridge. This marks an important step toward real choice in obesity care, helping more patients and doctors have informed conversations about the treatment options that may be right for them. Learn more and see the CMS Medicare GLP-1 Bridge Clinical Criteria: https://lnkd.in/extYYMKm
Eli Lilly and Company
Pharmaceutical Manufacturing
Indianapolis, Indiana 2,761,313 followers
About us
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
- Website
-
http://www.lilly.com/
External link for Eli Lilly and Company
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Indianapolis, Indiana
- Type
- Public Company
- Specialties
- Pharmaceutical Development, Pharmaceuticals, Biotech, and Biopharmaceuticals
Employees at Eli Lilly and Company
View 57k employees at Eli Lilly and Company
or
Locations
-
Primary
Get directions
Lilly Corporate Center
Indianapolis, Indiana 46285, US
Updates
-
New evidence shared at #EHA2026 for people living with previously treated #bloodcancer. See more from Lilly Oncology.
In a late-breaking oral presentation, Lilly shared results from a Phase 3 blood cancer study evaluating one of our medicines as part of a time-limited regimen for people with previously treated chronic lymphocytic leukemia. Learn more here: https://e.lilly/43DP15F European Hematology Association (EHA) #EHA2026 #BloodCancer #CLL
-
-
New clinical data will be shared at #EHA2026 in #myelofibrosis, a blood cancer with significant unmet needs. See more from Lilly Oncology.
In an oral presentation, initial clinical results will be shared from a Phase 1 study evaluating a first-in-class therapy for patients with previously treated myelofibrosis. Learn more here: https://e.lilly/43zIwkf European Hematology Association (EHA) #EHA2026 #Myelofibrosis
-
-
The FDA has approved a new dosing option for Lilly’s treatment for moderate-to-severe atopic dermatitis (#eczema). Learn more about this approval: https://lnkd.in/e5tskxAG
-
-
New science, new perspectives and a renewed sense of what’s possible for people living with obesity and type 2 diabetes: #ADA2026 moved us forward toward a new era of care. #WeAreLilly
-
Three Phase 3 trials. One consistent story. Today, we presented results from ACHIEVE-2, ACHIEVE-3, and ACHIEVE-5 — three studies evaluating our once-daily oral GLP-1 in adults with type 2 diabetes — at the #ADA2026 Scientific Sessions. Across all three studies, our medicine outperformed on blood sugar control and weight loss in this investigational use. We plan to submit to the U.S. FDA for type 2 diabetes by end of Q2 under the Commissioner's National Priority Review Voucher. The ACHIEVE program is establishing a compelling profile that could position our oral GLP-1 as a potential foundational treatment option. Read more: https://lnkd.in/e6sKG9Ct
-
-
Menopausal status is rarely evaluated in obesity research — yet it’s a critical window when hormonal shifts can accelerate fat accumulation. New post-hoc analyses from the ATTAIN clinical trial program of one of our obesity medicines, presented today at the #ADA2026 Scientific Sessions, begin to address this gap. Across both ATTAIN-1 (participants without diabetes) and ATTAIN-2 (participants with type 2 diabetes), women at every stage of menopause experienced meaningful, sustained weight reduction at 72 weeks on the highest dose. Read more: https://lnkd.in/eY83MNQZ
-
-
New analyses on one of our obesity medicines shed important light on an underexamined area of women's health: weight management across menopausal stages. Post-hoc analyses of the ATTAIN-1 and ATTAIN-2 trials presented at #ADA2026 found that women with obesity or overweight experienced significant weight loss at 72 weeks on the highest dose, regardless of menopausal status — pre, peri or postmenopausal. Menopausal status has rarely been evaluated in obesity treatment trials. This research begins to close that gap. Read more: https://lnkd.in/e45q8qhJ
-
-
Data presented so far at #ADA2026 is generating lots of conversation on the conference floor. The science is moving fast and the excitement about the future of diabetes and obesity care is building. #WeAreLilly
-
Adults with type 2 diabetes on our investigational triple agonist achieved significant A1C reductions in the TRANSCEND-T2D-1 study, presented today at #ADA2026 and published in The Lancet Group. At 40 weeks, patients achieved A1C reductions of up to 2 percent from a 7.9 percent baseline, and 90 percent of participants achieved an A1C below 7 percent, the American Diabetes Association's general target for type 2 diabetes. Patients also saw an average weight loss of 36.6 pounds on the highest dose, with weight loss not yet plateauing. Read more: https://lnkd.in/euMmu4td
-